GoLYTELY
(Polyethylene Glycol 3350)ApprovedSmall molecule
AstraZenecaIt's used to treat constipation by drawing water into the bowels to soften stool and make it easier to pass. It's also used to cleanse the bowels before medical procedures like colonoscopies.[2] GoLYTELY is currently approved and in use across 8 indications[4].[1]
GoLYTELY is one of 213 small molecule programs targeting Colorectal Carcinoma. It is currently in Approved.
8
Indications
19
Total Trials
4
Active Trials
212
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1GoLYTELY
AstraZenecaApproved
Eylea
RegeneronPreclinical
Emend IV
Merck & Co.Preclinical
PORTRAZZA
Eli LillyPreclinical
Andriol
AAuxilium
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Vascepa
AAmarin Pharma Inc.
Preclinical
Gas-X
PPortuguese Oncology Institute, Coimbra
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Constipation5 trials
Crohn's Disease2 trials
Cystic Fibrosis1 trial
Urogynecologic Surgery1 trial
9 more indications
Encephalopathy1 trial
Bowel Preparation for Colonoscopy1 trial
Urologic Surgery1 trial
Preop Laxatives in Robotic Urologic Surgery
Recruiting·—·Phase 4·NCT05805436·240 enrolled
Sources
References
- [1]
- [2]MedlinePlus Drug Information — GoLYTELY drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Polyethylene Glycol 3350. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company